1. Medicare Part D and beneficiaries could realize significant spending reductions with increased biosimilar use Publication: Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, March 2022 Subject(s): Biosimilar PharmaceuticalsDrug Costs -- legislation & jurisprudenceGovernment RegulationMedicare Part D -- economicsUnited StatesUnited States. Department of Health and Human ServicesCenters for Medicare & Medicaid Services (U.S.)
